Χώρα: Ευρωπαϊκή Ένωση
Γλώσσα: Ελληνικά
Πηγή: EMA (European Medicines Agency)
Quizartinib dihydrochloride
Daiichi Sankyo Europe GmbH
L01EX11
quizartinib
Antineoplastic agents, Protein kinase inhibitors
Λευχαιμία, μυελοειδής
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
Εξουσιοδοτημένο
2023-11-06
The website encountered an unexpected error. Try again later.
Διαβάστε το πλήρες έγγραφο
The website encountered an unexpected error. Try again later.
Διαβάστε το πλήρες έγγραφο